Covid-19 | Page 92 of 100 | Links Medicus Content Curation & Alerts in Medicine

New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments

9 Mar, 2021 | 02:49h | UTC

News release: New Study of Coronavirus Variants Predicts Virus Evolving to Escape Current Vaccines, Treatments – Columbia University Irving Medical Center

Original study: Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 – Nature

Commentary on Twitter

The B.1.351 and B.1.1.7 SARS-CoV-2 variants (first detected in South Africa and the UK, respectively) show increased resistance to antibody neutralization in laboratory experiments, according to a study in Nature. https://t.co/k0QBoeim6F pic.twitter.com/czyNYMBGxF

— Nature (@nature) March 8, 2021

Editorial | Avoiding exploitation in multinational covid-19 vaccine trials

9 Mar, 2021 | 02:43h | UTC

Avoiding exploitation in multinational covid-19 vaccine trials – The BMJ

Study confirms higher transmissibility of SARS-CoV-2 lineage B.1.1.7

9 Mar, 2021 | 02:47h | UTC

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England – Science

Commentary: Study confirms B.1.1.7 variant of SARS-CoV-2 is more transmissible – News Medical

Commentary on Twitter (thread – click for more)

Our paper “Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England” has now been published in Science (early release: https://t.co/8LRLp669LL). I’ve tweeted about this a few times before, so I’m going to focus here on some key messages. (1/8)

— Nick Davies (@_nickdavies) March 3, 2021

[Preprint] Systematic review: Characteristics of SARS-CoV-2 reinfection vs. persistent COVID-19

9 Mar, 2021 | 02:44h | UTC

SARS-CoV-2 Sequence Characteristics of COVID-19 Persistence and Reinfection – medRxiv

Commentary: How can physicians distinguish between COVID-19 persistence and SARS-CoV-2 reinfection? – News Medical

Ten things to consider when implementing rationing guidelines during a pandemic

9 Mar, 2021 | 02:46h | UTC

Ten things to consider when implementing rationing guidelines during a pandemic – Intensive Care Medicine

Commentary on Twitter

Rationing in #pandemic? Consider
1⃣identify scarce resources
2⃣exhaust ways to integrate
3⃣be clear/involve public
4⃣prognosis/age
5⃣responsibilities
6⃣pt goals/choice
7⃣disabilities, poverty, racism
8⃣prioritize
9⃣legal coverage
?impact on HCWs#COVID19 https://t.co/iSWVbqH3FY pic.twitter.com/bIoYmsSKQD

— Intens Care Med (@yourICM) March 7, 2021

Few pro athletes had inflammatory heart disease after COVID

9 Mar, 2021 | 02:41h | UTC

Few pro athletes had inflammatory heart disease after COVID – CIDRAP

Original study: Prevalence of Inflammatory Heart Disease Among Professional Athletes With Prior COVID-19 Infection Who Received Systematic Return-to-Play Cardiac Screening – JAMA Cardiology

RECOVERY trial: Colchicine arm stopped for lack of efficacy in patients hospitalized with COVID-19

7 Mar, 2021 | 20:16h | UTC

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19 – University of Oxford

Commentary: Cochicine does not improve mortality in COVID19 – St Emlyn’s

Commentary on Twitter

RECOVERY trial update:

Colchicine arm stopped for lack of efficacy in patients hospitalised with COVID-19.https://t.co/hcn9PytegJ pic.twitter.com/q09eddYXYL

— Martin Landray (@MartinLandray) March 5, 2021

RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19

7 Mar, 2021 | 20:15h | UTC

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet

Commentary on Twitter

The PRINCIPLE trial publishes its first peer reviewed paper, showing results from the study of azithromycin as a treatment for Covid-19 in the community. @TheLancet #UrgentCovidResearch #PRINCIPLETrial
?https://t.co/qKRI5PVpQk pic.twitter.com/BVQztDSvSC

— OxPrimaryCareSci (@OxPrimaryCare) March 5, 2021

WHO: The effects of virus variants on COVID-19 vaccines

7 Mar, 2021 | 20:09h | UTC

The effects of virus variants on COVID-19 vaccines – World Health Organization

Mask mandates and restaurant restrictions tied to fewer Covid-19 illnesses and deaths, CDC study says

7 Mar, 2021 | 20:07h | UTC

Mask mandates and restaurant restrictions tied to fewer Covid-19 illnesses and deaths, CDC study says – CNN

Original study: Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-Level COVID-19 Case and Death Growth Rates — United States, March 1–December 31, 2020 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter

A new @CDCMMWR finds that state-issued mask requirements are associated with the slowing of #COVID19 cases and deaths. Wearing a well-fitting mask consistently and correctly is one of the best ways we can protect ourselves and each other. Learn more: https://t.co/8YtmIMPMY0. pic.twitter.com/BLb56SGb2g

— CDC (@CDCgov) March 5, 2021

[Preprint] Genomics and epidemiology of a novel SARS-CoV-2 lineage P.1 – “P.1 may be 1.4–2.2 times more transmissible and 25-61% more likely to evade protective immunity elicited by previous infection with non-P.1 lineages”

7 Mar, 2021 | 20:05h | UTC

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil – medRxiv

Commentary: Brazil variant can reinfect virus survivors; COVID-19 vaccine antibodies pass into breast milk – Reuters

[Preprint] SARS-CoV-2 P.1 variant shows resistance to antibody neutralization

7 Mar, 2021 | 19:53h | UTC

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization – bioRxiv

Commentary: Brazilian SARS-CoV-2 P.1 variant shows resistance to antibody neutralization – News Medical

[Medicine based on data leaks…] Oxford study indicates AstraZeneca vaccine is effective against SARS-CoV-2 Lineage P.1

7 Mar, 2021 | 19:48h | UTC

Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says – Reuters

Commentary on Twitter

Reuters reporting on that leak that a lab study in Oxford for their vaccine (AstraZeneca) could stand up well to P1 ("Brazil" variant). Sounds like we'll know what they found soon?https://t.co/OvZebNk4gh (Corrected tweet. Thx @Bertrandization @CanadianOptom!)

— Hilda Bastian, PhD (@hildabast) March 6, 2021

[Preprint] Preliminary study shows Sinovac vaccine may not trigger sufficient antibody response to SARS-CoV-2 Lineage P.1

7 Mar, 2021 | 19:49h | UTC

Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination – The Lancet

Commentary: Sinovac vaccine may not trigger sufficient antibody response to Brazil variant: study – Reuters

Commentary on Twitter

1) In a preprint (to the Lancet), the new Brazilian #SARSCoV2 variant P.1. was found to reduce the neutralizing ability of post-COVID-19 antibodies by about 6-fold, compared with the B lineage.https://t.co/obYmktWFXr pic.twitter.com/3IPiUjHB3l

— Jonathan Cedernaes (@JCedernaes) March 2, 2021

[Preprint] Increased risk of hospitalization associated with infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark

7 Mar, 2021 | 19:46h | UTC

Increased Risk of Hospitalisation Associated with Infection with SARS-CoV-2 Lineage B.1.1.7 in Denmark – The Lancet

Commentary on Twitter (thread – click for more)

?~64% MORE SEVERE—The already more contagious #B117 variant from ?? is now found to increase risk of #COVID19 hospitalization by 64% versus other strains, says Denmark’s ?? CDC. Denmark sequences every cases—their data is the best, & now most worrisome.? https://t.co/F6w2JYEUnM pic.twitter.com/mngJoTBZtl

— Eric Feigl-Ding (@DrEricDing) March 4, 2021

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

7 Mar, 2021 | 19:43h | UTC

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines – Cell Host & Microbiome

Commentary on Twitter (thread – click for more)

Very good and important new data on the UK variant and vaccine response
"B.1.1.7 is not a neutralization escape variant of concern for COVID-19 vaccines"
"B.1.1.7 is unlikely to increase the risk of SARS-CoV-2 re-infection"https://t.co/DWzwBUDwY3 @cellhostmicrobe pic.twitter.com/iQv7mL9MHq

— Eric Topol (@EricTopol) March 4, 2021